Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS105 plus dalpiciclib and fulvestrant versus dalpiciclib and fulvestrant in PIK3CA-mutant HR-positive HER2-negative recurrent or metastatic breast cancer
CTR20254046Phase 3Active
- Sponsor
- Junshi Risen
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of JS105 in breast cancer, sponsored by Junshi Risen. Started Dec 2025; status: active.
02
Drugs
JS105
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254046.